2018
DOI: 10.1016/s2468-1253(18)30078-5
|View full text |Cite
|
Sign up to set email alerts
|

Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

8
281
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 249 publications
(298 citation statements)
references
References 27 publications
8
281
1
Order By: Relevance
“…Kudo et al [10] conducted the SILIUS study (a prospective controlled trial), and reported that 18 out of 96 patients who received sorafenib monotherapy were responders (response rate, 18.8%); OS was 27.2 months in these patients, which was significantly longer than the OS of 8.9 months in nonresponders (p < 0.001).…”
Section: Association Between Response To Molecular Targeted Agents Anmentioning
confidence: 99%
“…Kudo et al [10] conducted the SILIUS study (a prospective controlled trial), and reported that 18 out of 96 patients who received sorafenib monotherapy were responders (response rate, 18.8%); OS was 27.2 months in these patients, which was significantly longer than the OS of 8.9 months in nonresponders (p < 0.001).…”
Section: Association Between Response To Molecular Targeted Agents Anmentioning
confidence: 99%
“…Kudo et al [8] investigated sorafenib in a prospective, phase III comparative study, the SILIUS study. They noted a response by mRECIST in 18/96 patients receiving sorafenib monotherapy (response rate of 18.8%).…”
Section: Association Between Objective Response and Overall Survival mentioning
confidence: 99%
“…The BRISK-FL and LiGHT trials showed that brivanib and linifanib are not superior and, moreover, not noninferior, despite the fact that the trial designs allowed for assessment of noninferiority [5,6]. A superiority trial of sorafenib plus erlotinib (SEARCH trial) [7], a superiority trial of sorafenib plus doxorubicin (CALGB808028 trial), and a trial investigating sorafenib plus hepatic arterial infusion chemotherapy (HAIC) (SILIUS trial) [8] all failed. The results of two superiority trials comparing sorafenib with radioembolization called SARAH (SorAfenib versus Radioembolization in Advanced Hepatocellular carcinoma) [9] and SIRveNIB (Study to Compare Selective Internal Radiation Therapy [SIRT] Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma [HCC]) were also reported at EASL 2017 and ASCO 2017, although these trials failed as well [10].…”
Section: Introductionmentioning
confidence: 99%